Relevance of plasma lenvatinib concentrations and endogenous urinary cytochrome P450 3A activity biomarkers in clinical practice

• Main Authors: Masaki Kumondai (Author), Reika Ogawa (Author), Nagomi Hayashi (Author), Yurika Ishida (Author), Hanae Oshikiri (Author), Yuji Sato (Author), Masafumi Kikuchi (Author), Yu Sato (Author), Toshihiro Sato (Author), Masamitsu Maekawa (Author), Nariyasu Mano (Author)
• Format: Book
• Published: Wiley, 2024-08-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Lenvatinib (LEN), a multitarget tyrosine kinase inhibitor used in various cancer treatments, is mainly metabolized by cytochrome P450 3A (CYP3A) enzymes. The importance of therapeutic drug monitoring (TDM) in patients administered LEN has been proposed. Although some biomarkers of endogenou...